Fig. 4From: FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research—a systematic review and meta-analysisForest plot of mortality data, grouped by FLT3 inhibitor. Pooled data includes 60-day mortality data, but one trial (Levis) reported 30-day mortality only, which was used in this analysisBack to article page
